CCL21-CCR7 signaling promotes microglia/macrophage recruitment and chemotherapy resistance in glioblastoma - Sorbonne Université Accéder directement au contenu
Article Dans Une Revue Cellular and Molecular Life Sciences Année : 2023

CCL21-CCR7 signaling promotes microglia/macrophage recruitment and chemotherapy resistance in glioblastoma

Résumé

Abstract Glioblastoma (GBM) is the most common and fatal primary tumor of the central nervous system (CNS) and current treatments have limited success. Chemokine signaling regulates both malignant cells and stromal cells of the tumor microenvironment (TME), constituting a potential therapeutic target against brain cancers. Here, we investigated the C–C chemokine receptor type 7 (CCR7) and the chemokine (C–C-motif) ligand 21 (CCL21) for their expression and function in human GBM and then assessed their therapeutic potential in preclinical mouse GBM models. In GBM patients, CCR7 expression positively associated with a poor survival. CCL21–CCR7 signaling was shown to regulate tumor cell migration and proliferation while also controlling tumor associated microglia/macrophage recruitment and VEGF-A production, thereby controlling vascular dysmorphia. Inhibition of CCL21–CCR7 signaling led to an increased sensitivity to temozolomide-induced tumor cell death. Collectively, our data indicate that drug targeting of CCL21–CCR7 signaling in tumor and TME cells is a therapeutic option against GBM.
Fichier principal
Vignette du fichier
s00018-023-04788-7.pdf (10.03 Mo) Télécharger le fichier
Origine Publication financée par une institution
Licence

Dates et versions

hal-04509038 , version 1 (18-03-2024)

Licence

Identifiants

Citer

Luiz Henrique Geraldo, Celina Garcia, Yunling Xu, Felipe Saceanu Leser, Izabella Grimaldi, et al.. CCL21-CCR7 signaling promotes microglia/macrophage recruitment and chemotherapy resistance in glioblastoma. Cellular and Molecular Life Sciences, 2023, 80 (7), pp.179. ⟨10.1007/s00018-023-04788-7⟩. ⟨hal-04509038⟩
3 Consultations
6 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More